Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (3700)	5/8/2001 1:55:06 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

This is a very nice article by Lashinsky at TSC: Early Release of Drug-Test Results Raises Question of Fairness thestreet.com All the analysts get the abstracts when they first become available. The only saving grace is that the abstracts themselves are often somewhat out of date, and presenters often save some late-breaking goodies for the actual presentation. Peter

To: Biomaven who wrote (3700)	5/8/2001 3:18:07 PM
From: Harold Engstrom	Read Replies (1) \| Respond to of 52153

Peter, I think the PE for Biogen was reasonable without pricing in Rebif competition: 1) Growth rate is now likely to go negative and maybe double digit negative. 2) The pipeline stinks: there is Amevive and then a long distance to anything else. Sure there is Antegren and a couple others, but... 3) The company gives guidance for pipeline candidates and then just stops talking about them (Q: ever heard of Gelsolin? or CVT124? A: yes, but only after they went to sleep.) 4) Management is great, but this team is showing it is good at maintenance, not at sustaining growth. Amgen is overpriced. But, they will have growth and they do have a pipeline. They are deal-makers. How about MLNM? How many drug candidates do they say they will have soon? Something like 2,000, I think. What about VRTX? Somewhere I heard that the company expects to file 2-3 NDAs per year by 2005 and file 5 INDs each year (didn't they file 5 INDs this year?) It is disheartening to see a great company with great science groan along at such a slow pace when they have so much potential and are in the heart of biotechland. You may be right that there is no reason to sell way off, but I just can't see much upside unless Amevive explodes out of the gates.